Patient deaths force Astellas to write off $540M of their $3B gene therapy buyout as timeline grows and target group shrinks
Astellas no longer believes that last year’s $3 billion acquisition is worth $3 billion.
The Japanese pharma posted a notice on its
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
